Nantahala Capital Management LLC acquired a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,359,993 shares of the biotechnology company's stock, valued at approximately $19,753,141. Nantahala Capital Management LLC owned about 1.05% of ADMA Biologics as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. Summit Securities Group LLC acquired a new stake in ADMA Biologics in the fourth quarter valued at $29,000. iSAM Funds UK Ltd acquired a new position in shares of ADMA Biologics during the 3rd quarter worth $34,000. Morse Asset Management Inc acquired a new position in shares of ADMA Biologics during the 4th quarter worth $44,000. Nkcfo LLC purchased a new stake in shares of ADMA Biologics in the 4th quarter worth about $47,000. Finally, EverSource Wealth Advisors LLC boosted its position in shares of ADMA Biologics by 385.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company's stock worth $50,000 after buying an additional 2,180 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
ADMA has been the topic of a number of research reports. Zacks Research cut shares of ADMA Biologics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, August 4th. Mizuho cut their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating for the company in a research report on Wednesday, July 15th. Canaccord Genuity Group reduced their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, May 7th. Weiss Ratings reiterated a "hold (c)" rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Finally, Wall Street Zen cut shares of ADMA Biologics from a "buy" rating to a "hold" rating in a research note on Monday, May 4th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, ADMA Biologics currently has a consensus rating of "Hold" and an average price target of $18.67.
Check Out Our Latest Stock Report on ADMA
ADMA Biologics Stock Performance
NASDAQ ADMA opened at $9.34 on Friday. The company has a quick ratio of 3.81, a current ratio of 6.97 and a debt-to-equity ratio of 0.49. ADMA Biologics Inc has a fifty-two week low of $7.21 and a fifty-two week high of $20.46. The business has a fifty day moving average of $9.07 and a 200-day moving average of $10.54. The stock has a market cap of $2.09 billion, a price-to-earnings ratio of 13.34 and a beta of 0.74.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting analysts' consensus estimates of $0.16. The business had revenue of $124.39 million for the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The business's revenue for the quarter was up 2.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.14 earnings per share. As a group, analysts predict that ADMA Biologics Inc will post 0.78 earnings per share for the current fiscal year.
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
